Company Active LTD

Company profile

Askbio UK Ltd

Askbio UK Ltd is a UK company with status active founded in 2010 based in Scotland.

CRN
SC384375
Founded
2010
Age
15

Overview

Legal name
ASKBIO UK LTD
Region
Scotland
Registered address
ROSLIN INNOVATION CENTRE
EASTER BUSH CAMPUS
MIDLOTHIAN
SCOTLAND
EH25 9RG
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller
1
Company Active LTD
Askbio UK Ltd
CRN SC384375
2
Direct and ultimate controller
HRB 48248
CRN HRB 48248

Latest accounts

Financial period: 1 Jan 2024 to 31 Dec 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
£1,755,982
Employees
54

Company events

Reference milestones and recent Companies House filing stream events.

7 events
30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

19 Jul
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

01 Jul
2026

Termination Secretary Company With Name Termination Date

Officers

TM02 | Transaction MzUyOTg1MTQ4OWFkaXF6a2N4

Published 01 Jul 2026 13:14

05 Jul
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

01 Oct
2024

Accounts With Accounts Type Full

Accounts Analysed

AA | Transaction MzQzNzc5MDkzMGFkaXF6a2N4

Published 01 Oct 2024 08:08

27 Aug
2010

Incorporated

Inception

Company registered at Companies House

Public funding

7 awards
First funded
2012
Funded years
2012, 2013, 2014, 2016, 2018
Age at first award
1 years

Projects

2018 Collaborative R&D Lead participant

Development of a novel inducible expression system for the manufacture of therapeutic proteins from CHO cells.

1 Mar 2018 to 31 Mar 2020

Awarded
£72,582
Total cost £103,688

Production of biopharmaceuticals that are toxic or have detrimental effects on the growth of the host cell line is very challenging. To overcome this challenge researchers have developed a number of promoters allowing control of protein expression during the bioproduction process. The primary aim of that research was to enable a 2-step bioprocessing platf...

2016 Collaborative R&D Lead participant

Enhanced Vector Bioprocessing Technologies for Cell and Gene Therapies

1 Jul 2016 to 30 Jun 2019

Awarded
£971,427
Total cost £1,387,753

Evolving therapeutic approaches of cell and gene therapy are harnessing the power of viruses in order to modify genomes of cells to produce a therapeutic effect. Such therapies are starting to show efficacy in the clinic, but one of the key challenges to their widespread use is the ability to make large quantities of virus at a low cost. This project seek...

2014 Collaborative R&D

A toolchest for rapid bootstrapping of novel chassis organisms

1 Aug 2014 to 31 Oct 2015

Awarded
£58,819
Total cost £98,031

The bioscience industry currently relies on a small number of organisms to produce the majority of the recombinant products on the market. A collaboration between two UK synthetic biology Synthace and Synpromics and University College London, this project combines cutting edge computational techniques with multifactorial experimental design to develop a n...

2014 Collaborative R&D Lead participant

Engineering Promoters for Specific Antigen Expression in a Synthetic DNA Vaccine Construct

1 Jul 2014 to 31 Dec 2015

Awarded
£111,896
Total cost £186,494

The collaboration between Synpromics Ltd. and Touchlight Genetics Ltd. will combine two highly innovative and complementary technology platforms to develop an improved approach to developing DNA vaccines. The project will leverage Synpromics's proprietary technology to rationally design synthetic promoters that drive cell-specific antigen expression and t...

2014 Collaborative R&D Lead participant

Adaptable Synthetic Promoters to Optimise Industrial Competitiveness of Engineered Yeast

1 Jun 2014 to 30 Nov 2015

Awarded
£150,455
Total cost £250,758

The collaboration between Synpromics and Ingenza is focused on developing proprietary protein production systems in engineered yeast strains that improve on currently available alternatives by incorporating novel synthetic promoter constructs rationally designed to drive optimal gene expression. The enabling technology that the project aims to deliver wil...

2013 Feasibility Studies Lead participant

Promoters for Improved Protein & Biopharmaceutics Production in Mammalian Cells

1 Oct 2013 to 30 Sep 2015

Awarded
£143,533
Total cost £191,381

Enhancing methods of protein expression is fundamentally important to new drug development and the efficient production of biopharmaceuticals. The consortium aims to develop a novel means of designing and constructing synthetic promoters that can be employed on an industrial scale to drive the expression of proteins for commercial applications. This will ...

2012 Collaborative R&D

Highly-predictive cell-based analysis using biodegradable transfection technology

1 Aug 2012 to 31 Oct 2014

Awarded
£34,684
Total cost £69,367

The project will deliver new tools that can be used to test potential new drugs, food constituents with possible health benefit, and which also offer a new approach to measuring the effect on human health of particles present in our domestic or workplace environment. These tools will be based upon living cells that are placed in situations where they repr...

Product types

Collaborative R&D Feasibility Studies